The present application relates to an inhibitor of fusion between a viral membrane from an enveloped virus and a cell membrane, where the viral membrane comprises a fusion mediating protein including a C-terminal peptide. The inhibitor comprises the C-terminal peptide of the fusion mediating protein from an enveloped virus and tocopherol or a derivative or pharmaceutically acceptable salt thereof attached to the C-terminal peptide. Also disclosed is a pharmaceutical composition including the inhibitor as well as methods of inhibiting viral fusion, blocking viral spread, and preventing or treating viral infection, with the inhibitor or pharmaceutical composition.

The present invention provides targeting lipids of structure
L.sup.100-linker-L.sup.101  (CI),
where L.sup.100 is a lipid, lipophile, alkyl, alkenyl or alkynyl, L.sup.101 is a ligand or —CH.sub.2CH.sub.2(OCH.sub.2CH.sub.2).sub.pO(CH.sub.2).sub.qCH.sub.2-ligand, p is 1-1000, and q is 1-20. In addition, the invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo.

The present invention provides targeting lipids of structure
L.sup.100-linker-L.sup.101  (CI),
where L.sup.100 is a lipid, lipophile, alkyl, alkenyl or alkynyl, L.sup.101 is a ligand or —CH.sub.2CH.sub.2(OCH.sub.2CH.sub.2).sub.pO(CH.sub.2).sub.qCH.sub.2-ligand, p is 1-1000, and q is 1-20. In addition, the invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo.

The present invention relates to a docetaxel albumin nanoparticle pharmaceutical composition, a preparation method therefor, and a use thereof for manufacturing drugs for treating cancer. The pharmaceutical composition comprises docetaxel, albumin and amino acid(s), wherein the weight ratio between albumin and docetaxel is no more than 50, preferably is 20:1 to 1:1, and the weight ratio between amino acid(s) and docetaxel is not less than 0.5, preferably is 1:1 to 20:1.

The present invention relates to a docetaxel albumin nanoparticle pharmaceutical composition, a preparation method therefor, and a use thereof for manufacturing drugs for treating cancer. The pharmaceutical composition comprises docetaxel, albumin and amino acid(s), wherein the weight ratio between albumin and docetaxel is no more than 50, preferably is 20:1 to 1:1, and the weight ratio between amino acid(s) and docetaxel is not less than 0.5, preferably is 1:1 to 20:1.

Duocarmycin-based antibody-drug conjugates can be readily separated from non-conjugated duocarmycin linker-drug in a composition that contains a solvent system of water and acetonitrile and that has 30% to 60% acetonitrile.

Duocarmycin-based antibody-drug conjugates can be readily separated from non-conjugated duocarmycin linker-drug in a composition that contains a solvent system of water and acetonitrile and that has 30% to 60% acetonitrile.

A composition comprising an organic photoactivator, a gasotransmitter salt which converts into a gasotransmitter via electron transfer, and an electron donor which donates an electron to the photoactivator when the photoactivator is in a photo-excited state.

Disclosed are stable, non-irritating, retinoid containing formulations and delivery systems for topical application to the skin. The disclosed topical formulations and delivery systems provide controlled release of the retinoid to the skin for the treatment of amenable skin conditions as well as for improvement of aesthetic skin properties. Also provided are methods for the formulation, manufacture and use of the disclosed retinoid containing formulations and delivery systems.

Disclosed are stable, non-irritating, retinoid containing formulations and delivery systems for topical application to the skin. The disclosed topical formulations and delivery systems provide controlled release of the retinoid to the skin for the treatment of amenable skin conditions as well as for improvement of aesthetic skin properties. Also provided are methods for the formulation, manufacture and use of the disclosed retinoid containing formulations and delivery systems.